Larotrectinib, a first-generation TRK inhibitor, is an ATP-competitive molecule that has demonstrated efficacy in multiple cancers, including infantile fibrosarcoma, thyroid carcinoma, and NSCLC [5]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.